Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.75 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.42 |
| ▸ | GRB2 | P62993 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.40 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.40 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL7441032 | 1.00 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL31651400 | 1.00 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL2298893 | 0.94 | SLC7A5 (0.67) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL30527819 | 0.94 | SLC7A5 (0.67) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL15602684 | 0.87 | SLC7A5 (0.90) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL25241602 | 0.87 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| D-Leucine SCHEMBL42012 | 0.87 | — | — | |
| Leucine SCHEMBL2478164 | 0.87 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL8568063 | 0.87 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL20362356 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087935-B1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INT LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20030203975-A1 | Anti-cancer agents | BTG INTERNATIONAL LIMITED (GB) | 2003-10-30 | — | — | US | disclosed |
| EP-0906272-B1 | PEPTIDES | NOVARTIS AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| EP-1087935-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065866-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 1999-12-23 | — | — | WO | disclosed |
| EP-0906272-A2 | PEPTIDES | Novartis AG (CH) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997047593-A2 | PEPTIDES | NOVARTIS AG (CH) | 1997-12-18 | — | — | WO | disclosed |
| US-5689039-A | HERBICIDE RESISTANCE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0577775-A4 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES. | RHONE POULENC RORER INT (US) | 1995-01-11 | — | — | EP | disclosed |
| EP-0577775-A1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1994-01-12 | — | — | EP | disclosed |
| WO-1992017196-A1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203975-A1 | Anti-cancer agents | TOP2B, TOP2A, TOP1 | SLC7A5 757/4885SLC1A3 2822/4885SLC1A2 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.